Keeping in mind that the readouts entailed cell culture experiments and mouse models of APS-related disorders, the present work shows that 1N11, a fully human antibody that disrupts aPL recognition of β2-GPI, may afford another opportunity to develop an anti-β2-GPI mAb as a therapy. The gene discussed is APOH; the disease is autoimmune polyendocrinopathy.